The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?

Atsushi Oba,Christopher H. Lieu,Cheryl Meguid,Sarah Lindsey Davis,Alexis D. Leal,Tom Purcell,Gentry Teng King,Karyn A. Goodman,Tracey E. Schefter,Ana Gleisner,Steven A. Ahrendt,Stephen Leong,Wells A. Messersmith,Richard D. Shulick,Marco Del Chiaro

The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?

2020

Atsushi Oba
Christopher H. Lieu
Cheryl Meguid
Sarah Lindsey Davis
Alexis D. Leal
Tom Purcell
Gentry Teng King
Karyn A. Goodman
Tracey E. Schefter
Ana Gleisner
Steven A. Ahrendt
Stephen Leong
Wells A. Messersmith
Richard D. Shulick
Marco Del Chiaro

685Background: For borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC), neoadjuvant (NAT) FOLFIRINOX or gemcitabine plus nab-paclitaxel (GnP) are standard treatment options an...

Keywords:

Pancreatic cancer
Internal medicine
Oncology
Chemotherapy
Medicine
Pathology
Standard treatment
Gemcitabine
FOLFIRINOX
locally advanced pancreatic cancer
borderline resectable

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations